Getting Mounjaro covered by insurance comes down to one key fact: it’s FDA-approved only for type 2 diabetes, not weight loss. Without a type 2 diabetes diagnosis, most insurers won’t cover it. Even with the right diagnosis, you’ll likely need to clear several hurdles, including prior authorization and proof that you’ve tried cheaper medications first. A month’s supply runs roughly $1,094 without coverage, so understanding the process is worth your time.
Why Your Diagnosis Determines Everything
Mounjaro (tirzepatide) is approved as an add-on to diet and exercise for improving blood sugar control in adults and children 10 and older with type 2 diabetes. That’s it. Insurance formularies categorize it under diabetes medication benefits, which means your claim needs to include a type 2 diabetes diagnosis code.
If your doctor is prescribing Mounjaro primarily for weight loss, you’re in a different situation. Eli Lilly sells the exact same drug under a separate brand name, Zepbound, for chronic weight management. The company created two brands specifically so each could follow its own insurance coverage pathway. The problem: many insurance plans explicitly exclude weight loss medications, making Zepbound harder to get covered. Meanwhile, Mounjaro prescribed off-label for obesity without a type 2 diabetes diagnosis usually won’t be covered either. As the National Association of Insurance Commissioners notes, these drugs generally aren’t covered unless you have a type 2 diabetes diagnosis, though some plans may make exceptions if you have obesity-related conditions like high cholesterol or high blood pressure.
What Insurers Require for Approval
Almost every plan requires prior authorization for Mounjaro. This means your doctor’s office submits paperwork proving you meet specific clinical criteria before the pharmacy can fill your prescription. The exact requirements vary by insurer, but here’s what most plans ask for, based on criteria from major health plans:
- Confirmed type 2 diabetes diagnosis. Your doctor must submit documentation. Common proof includes an A1C of 6.5% or higher, a fasting blood glucose of 126 mg/dL or above, or a random blood glucose over 200 mg/dL with symptoms like excessive thirst or frequent urination.
- A trial of metformin first. Most plans require that you’ve tried metformin for at least three months at an appropriate dose and either didn’t respond well enough, couldn’t tolerate it, or have a medical reason you can’t take it. This is called step therapy, and it’s the most common barrier.
- Failure of other GLP-1 medications. Some plans go further, requiring documented evidence that you tried and didn’t respond to formulary alternatives like Ozempic, Rybelsus, or generic liraglutide before they’ll approve Mounjaro. Your doctor needs to submit records showing what happened with those medications.
- Age requirement. Some plans restrict coverage to patients 18 and older, even though the FDA approval now extends to age 10.
- No duplicate therapy. You can’t use Mounjaro alongside another GLP-1 medication. If you’re currently on one, the insurer will deny the claim.
The prior authorization form typically needs to be completed by your prescriber, not you. But knowing what’s required puts you in a position to have an informed conversation with your doctor and make sure the right documentation gets submitted the first time.
How to Strengthen Your Case Before Applying
The most common reason for denial is incomplete documentation. Before your doctor submits the prior authorization, make sure your medical records clearly show your type 2 diabetes diagnosis, your current A1C or blood glucose results, and a history of every diabetes medication you’ve tried along with why each one was stopped or insufficient.
If you haven’t yet tried metformin, your insurer will almost certainly require it first. Some plans accept a documented contraindication (for instance, kidney problems that make metformin unsafe), so if there’s a medical reason you can’t take it, make sure your doctor notes that explicitly. The same goes for other GLP-1 medications your plan considers preferred alternatives. If your doctor believes Mounjaro is the right choice from the start, the records need to explain why the alternatives aren’t appropriate for you specifically.
Having your prescriber be an endocrinologist or diabetes specialist can also help. Some plans prefer or require specialist involvement, and a letter from a specialist carries more weight in the review process.
What to Do If You’re Denied
A denial isn’t the end. You have the right to appeal, and appeals do succeed. In one New York state case reviewed by the Department of Financial Services, an insurer denied Mounjaro coverage but was overturned on appeal after the patient’s doctor documented that the patient had tried and failed both Ozempic and Rybelsus. The appeal letter showed that Mounjaro was causing fewer side effects than the alternatives, and that was enough to meet the plan’s own criteria for covering a non-formulary drug.
When you receive a denial letter, it should state the specific reason. The most common reasons include: the insurer considers it non-formulary and wants you to try preferred alternatives first, the documentation submitted was incomplete, or the diagnosis doesn’t match the approved indication. Each of these has a different fix.
For your appeal, gather the following:
- A letter from your prescriber explaining why Mounjaro is medically necessary for you, referencing your specific lab results and medication history.
- Medical records showing your treatment timeline, including dates, dosages, and outcomes for every diabetes medication you’ve used.
- Evidence of side effects or inadequate response to the alternatives your insurer wanted you to try. Office visit notes documenting these problems are especially useful.
Most plans offer two levels of internal appeal, and if those fail, you can request an external review by an independent third party. Your state’s department of insurance oversees this process. Time limits apply, so check your denial letter for deadlines.
The Manufacturer Savings Card
If you have commercial insurance (not Medicare or Medicaid), Eli Lilly offers a savings card that can bring your cost down to as little as $25 for up to a three-month supply. If your pharmacy can’t fill a three-month prescription, the card still works for a one-month fill at $25. This card is designed to reduce your copay or coinsurance after insurance, so you typically need some level of insurance coverage for it to apply.
You can get the savings card through Mounjaro’s official website. It’s worth activating even if your insurance covers the drug, since it can eliminate or significantly reduce whatever your plan leaves you owing.
If You Don’t Have Type 2 Diabetes
Your options are more limited. Most insurers won’t cover Mounjaro without a type 2 diabetes diagnosis, and prescribing it off-label for weight management puts you in a coverage gray area that rarely works out. If your goal is weight loss, ask your doctor about Zepbound instead, since it’s the same molecule approved for chronic weight management in adults with a BMI of 30 or higher (or 27 with at least one weight-related condition). Coverage for Zepbound is still inconsistent, with many plans excluding weight loss drugs entirely, but it’s the correct pathway if obesity is the primary concern.
Some patients with prediabetes or insulin resistance fall into an in-between space. Insurance plans vary on whether conditions like polycystic ovary syndrome or metabolic syndrome can justify coverage. These situations are worth discussing with your doctor, but expect an uphill process and plan for the possibility of paying out of pocket.